ARCHIVES

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

This article is from The Cancer Letter archive.

Vol. 17 No. 31 | August 2, 1991

Download PDF Visit The Full Archive

Related Articles

FDA news: Von Eschenbach to FDA staff: “I did not come here to be a figurehead…. While I am here, I will lead.”

November 4, 2005

Faulty Estimates Led NCI To Overstate Black-White Cancer Disparity In Atlanta

September 20, 2002

AACR President Kripke Calls For Dedicated Translational Research

March 11, 1994

Nine More Reported In Range Of CCOP 3 Recompetition

February 2, 1990

FDA Oncology Unit Fastest in Approvals Despite Having Highest Workload

May 9, 2014

Clinical Oncology Study Section In Draft; ET2 May Be Eliminated, NIH Official Says

February 13, 1998